GUANZE MEDICAL (02427) has issued a profit warning, projecting a net loss attributable to shareholders of no more than RMB 45 million for the six months ending June 30, 2026.

This compares with a profit attributable to shareholders of approximately RMB 3.4 million for the corresponding period in 2025. The board attributes the anticipated loss to several key factors, including a decline in gross profit driven by a product mix shift toward lower-margin medical imaging devices and cloud services, alongside reduced sales of higher-margin software.

Additional pressures stem from increased depreciation on fixed assets recognized in cost of sales, administrative expenses, and distribution costs, as well as higher research and development spending. Furthermore, share-based payment expenses have risen following the vesting of share awards in February 2026, which occurred as a result of a change in the controlling shareholder.